KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Zeus Hygia launches Metaberine in Europe and US markets

Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches